Swiss Competition Commission: No Solid Evidence in Novartis Patent Investigation, New Inquiry Sparks Negative Market Speculation!

The Swiss competition Commission (COMCO) announced in a statement on Thursday that it had decided to stop its investigation into Novartis and decided to open a new investigation into whether there had been any blocking of the use of patents. There will be no legal consequences.

In a formal statement, COMCO explained in detail that the committee has been in the process of investigating the matter since September 2022. The main purpose of the investigation is to verify whether the pharmaceutical giant is trying to illegally maintain an exclusive position on the market for its drugs through a series of patent infringement lawsuits.

In a statement, Novartis said: "After an in-depth investigation, COMCO confirmed that Novartis' actions were ultimately consistent with normal practice in the field of patent law. In the course of the investigation, no material evidence was found to substantiate the above illegal restriction of market competition."